Latest Venture Capital News

Associate Global Partners has partnered with US investment manager ARK to bring the ARK Venture Fund to Australian wholesale investors, expanding AGP's access to high-growth private companies focused on technological disruption.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

Centuria Industrial REIT (ASX: CIP) detailed its strategy to expand data centre assets leveraging its urban infill industrial portfolio, aiming for real estate returns through development and long-term leases.

Diatreme Resources has finalised the sale of its Cape Flattery Silica Project to a joint venture with Sibelco, receiving $2.1 million in reimbursements and positioning for up to $7.4 million in total funding.

Scalare Partners has acquired Fishburners, Australia’s largest startup community, to deepen its founder network and expand integrated support services across the country.

dorsaVi has secured a 12-month renewal of its Department of Defense-funded research with Georgia Southern University, advancing real-time gait optimisation to reduce military training injuries and laying groundwork for its exoskeleton and neuromorphic computing strategy.

dorsaVi has launched a multi-year partnership with Taiwan’s ITRI and NTU to develop its proprietary RRAM platform at the 22-nm node, complemented by a new advisory board and neuromorphic IP acquisition, positioning the company at the forefront of ultra-edge AI hardware.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Scalare Partners (ASX:SCP) reported a striking 771% year-on-year revenue increase to $5.26 million in Q3 FY26, alongside positive operating cashflow of $2.84 million, driven by ecosystem growth and new partnerships.

Kinetiko Energy is advancing a staged development strategy to unlock its 6 trillion cubic feet gas resource in South Africa, targeting first revenues within 18 months through a capital-efficient, risk-managed approach.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.